CEO’S CORNER

Horizon Therapeutics

U.S. sues to prevent Amgen from acquiring Horizon Therapeutics for $27.8 billion.

According to the Federal Trade Commission, the agreement would allow Amgen to take advantage of its size to stifle competition for two pricey Horizon medications. In a lawsuit filed on Tuesday, the Federal Trade Commission argued that Amgen's $27.8 billion purchase of Horizon Therapeutics will stifle competition in the pharmaceutical sector.

lacinia nisl, vel nostra nunc eleifend arcu leo.

bundling.

Action by the commission. after years of indicating that it would be stricter in examining pharmaceutical deals, is its most forceful yet. By a vote of 3 to 0, its commissioners agreed to file the lawsuit.

Presented By Kennedy Lucas Publishings LC

Senior Commission officer Holly Vedova stated that the case "sends a clear signal to the market: The F.T.C. won't hesitate to challenge mergers that enable pharmaceutical conglomerates to entrench their monopolies at the expense of consumers and fair competition."

Amgen stated that it will not package the two Horizon medications and that the merger did not provide any competitive difficulties.

Nulla nunc lectus porttitor vitae pulvinar magna. Sed et lacus quis enim mattis nonummy sodales.

One of the biggest Horizon do not market rival goods, this situation is rare.